ALKS 2680 is named as a drug or biological intervention in 2 clinical trials in our USA trial register, 2 of which are recruiting. The lead sponsor is Alkermes, Inc.. Registered phases: Phase 2 and Phase 2/3. Conditions studied include Idiopathic Hypersomnia; Narcolepsy Type 1; Narcolepsy Type 2.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06767683 | A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia (ClinicalTrials.gov ↗) Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia |
Phase 2/3 | Recruiting |
| NCT06843590 | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia (ClinicalTrials.gov ↗) Idiopathic Hypersomnia |
Phase 2 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Idiopathic Hypersomnia | 2 |
| Narcolepsy Type 1 | 1 |
| Narcolepsy Type 2 | 1 |
| Lead sponsor | Trials |
|---|---|
| Alkermes, Inc. | 2 |
| Register | ALKS 2680 trials |
|---|---|
| Clinical trials in USA | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ALKS 2680 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ALKS 2680 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.